GlassScriptPhysician profile
Theodore Michael Kopp
NPI 1437348711
$5,646.85
in general payments reported to CMS, 2019-2025
34 companies · $384 in 2025
The $384 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $674 · 2021: $905 · 2022: $778 · 2023: $901 · 2024: $1,097 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,004.91 | 2019-2025 | Relistor |
| Horizon Therapeutics Plc | $472.14 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $458.97 | 2019-2025 | Belbuca |
| Valinor Pharma, LLC | $389.22 | 2023-2025 | Movantik |
| Forte Bio-Pharma LLC | $368.35 | 2022-2024 | Prolate, Nalocet |
| Arbor Pharmaceuticals, INC. | $281.42 | 2019-2022 | |
| Daiichi Sankyo INC. | $148.14 | 2019 | |
| Medtronic, INC. | $132.99 | 2021-2024 | Intellis Adaptivestim, Accurian |
| Scilex Pharmaceuticals INC. | $129.02 | 2019-2022 | |
| Medtronic USA, INC. | $122.69 | 2020 | |
| Almatica Pharma LLC | $106.17 | 2022-2023 | Gralise |
| Pacira Therapeutics, INC. | $94.94 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $93.77 | 2023-2024 | Horizant, Horizant |
| Biodelivery Sciences International, INC. | $92.91 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $68.81 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $68.34 | 2024 | Levorphanol Tartrate |
| Redhill Biopharma INC. | $60.46 | 2021-2022 | |
| Boston Scientific Corporation | $59.78 | 2019-2024 | |
| Hikma Pharmaceuticals USA | $58.83 | 2023-2024 | Kloxxado |
| Takeda Pharmaceuticals U.S.A., INC. | $55.47 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $48.41 | 2025 | |
| Zyla Life Sciences, INC. | $43.36 | 2019-2020 | |
| Pfizer INC. | $42.01 | 2019 | |
| Shionogi INC | $35.12 | 2019 | |
| Kaleo, INC. | $33.19 | 2019 | |
| Biotronik Nro, INC. | $33.16 | 2025 | Prospera |
| Currax Pharmaceuticals LLC | $30.70 | 2019-2020 | |
| Tonix Medicines, INC. | $22.99 | 2025 | Tonmya |
| Idorsia Pharmaceuticals US INC | $19.65 | 2022 | |
| Mdd US Operations, LLC | $19.53 | 2019 | |
| Ibsa Pharma INC. | $14.70 | 2023 | Tirosint, Licart |
| Nevro Corp. | $13.64 | 2019 | |
| Novo Nordisk INC | $11.79 | 2019 | |
| Medline Industries LP | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Kopp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.